Publications

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1620

Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1590

Activity of Ceftazidime-Avibactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals. Lead author: M Castanheira presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1443

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019). Lead author: H Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #2020

Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates. Lead author: PR Rhomberg, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1258

Comparative Epidemiological Analysis of Serratia marcescens using PFGE and Whole Genome Sequence Methods. Lead author: LM Deshpande presented at ID Week 2020, October 21-22, Virtual Conference
Poster #826

Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1629

Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018–2019) Stratified by Infection Type. Lead author, MD Huband, presented at IDWeek 2020, October 21-22, Virtual Conference.

Poster #1260

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. by Sader HS, Carvalhaes CG, Duncan LR, Flamm RK and Shortridge D. published in J. Antimicrob. Chemother. 2020; 75 (10): 2907-2913

Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States medical centers in 2016-2018. by Sader HS, Carvalhaes CG, Streit JM, Doyle TB and Castanheira M. published in Microb. Drug Resist. 2021; 27 (3): 342-349

Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and beta-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. by Castanheira M, Doyle TB, Hubler C, Sader HS and Mendes RE. published in Int. J. Antimicrob. Agents. 2020; 56 (1): 106011, 2020

In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018). by Huband MD, Lindley JM, Mendes RE, Fedler KA, Benn VJ, Zhang J, Zhong G, Li L, Zhang M, Tan X and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (4): 115191

Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, beta-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019. by Sader HS, Streit JM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2020; 99 (1): 115195

Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide. by Sader HS, Duncan LR, Arends SJR, Carvalhaes CG and Castanheira M. published in Antimicrob. Agents Chemother.: 2020; 64 (11): e01433

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. by Pfaller MA, Shortridge D, Arends SJR, Duncan LR, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (1): 115101.

Activity of Meropenem-Vaborbactam and Comparator Agents Tested against Enterobacterales Isolates from the United States Analyzed by Site of Infection Lead author: D Shortridge presented at ASM Microbe 2020, June 18-22, Chicago IL, USA
Poster #3804

Antimicrobial activity of ceftolozane-tazobactam and comparators against clinical isolates of Haemophilus influenzae from the United States and Europe. by Sader HS, Carvalhaes CG, Duncan LR and Shortridge D. published in Antimicrob. Agents Chemother. 2020;64 (5): e00211

Activity of plazomicin tested against Enterobacterales isolates collected from U.S. Hospitals in 2016-2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides. by Castanheira M, Sader HS, Mendes RE and Jones RN. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02418

In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates. by Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, Liu Q and Flamm RK. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02375

Omadacycline in vitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. by Mendes RE, Huband MD, Streit JM, Castanheira M and Flamm RK. published in Diagn. Microbiol. Infect Dis. 2020; 97 (3):115054.

Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015-2018). by Sader HS and Jones RN. published in Clin. Microbiol. Infect. 2020; 26 (5): 658-659

Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of Enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European medical centers, 2016 to 2018. by Carvalhaes CG, Sader HS, Flamm RK, Streit JM and Mendes RE. published in Antimicrob. Agents Chemother. 2020; 64 (4): e00175

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program. by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2019; 21: 60-64

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide by Sader HS, Rhomberg PR, Duncan LR, Locher HH, Dale GE and Flamm RK. published in J. Antimicrob. Chemother. 2020; 75 (6): 1518-1524

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist. 2020; 20: 118-123

Bacterial and fungal pathogens isolated from patients with bloodstream infection: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). by Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 97 (2): 115016, 2020.

Activity of Omadacycline and Comparator Agents against Bacterial Pathogens from the United States by Infection Type (2019). Lead author: MD Huband. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 1019.
Poster #P1143

Evaluation of Tedizolid and Comparators’ Activity Against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections from Paediatric Patients in Europe and Surrounding Countries (2015-2019). Lead author: CG Carvalhaes. This poster was originally intended for presentation at the 30th ECCMID (Paris, France; April 18-21, 2020). This meeting was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book (Abstract 2338).
Poster #P1156

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates Collected from US Medical Centers in 2016-2018. Lead author: HS Sader. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 473.
Poster #P3598

Resistance Mechanisms Associated with Pleuromutilins among Gram-Positive Clinical Isolates from the Worldwide Surveillance Program for Lefamulin in 2018. Lead author: RE Mendes. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 1322.
Poster #P0962

Tedizolid Activity against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019). Lead author: CG Carvalhaes. This poster was originally intended for presentation at the 30th ECCMID (Paris, France; April 18-21, 2020). This meeting was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book (Abstract 2359)
Poster #P1174

In Vitro and In Vivo Activity of Manogepix/Fosmanogepix, a Novel Antifungal with Activity against Aspergillus and Rare Moulds. Lead author: MD Huband presented at 9th Advances Against Aspergillosis and Mucormycosis (AAAM) 2020, February 27-29, Lugano, Switzerland
Poster #27

Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. by Flamm RK, Duncan LR, Hamed KA, Smart JI, Mendes RE and Pfaller MA. published in Antimicrobial agents and chemotherapy. in press, 2020.

In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018. by Messer SA, Carvalhaes CG, Castanheira M and Pfaller MA published in Diagn. Microbiol. Infect. Dis., 2020; 97 (1): 115007

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016-2018. by Pfaller MA, Huband MD, Shortridge D and Flamm RK published in Antimicrobial agents and chemotherapy., 2020: 64 (5); e02488

First report of bla _VIM-4– and mcr-9-coharboring Enterobacter species isolated from a pediatric patient. by Chavda KD, Westblade LF, Satlin MJ, Hemmert AC, Castanheira M, Jenkins SG, Chen L and Kreiswirth BN published in mSphere. 2019; 4 (5): e00629

Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018. by Castanheira M, Doyle TB, Kantro V, Mendes RE and Shortridge D published in Antimicrob. Agents Chemother. 2020; 64 (2): 01951

Correlation between broth microdilution and disk diffusion results when testing ceftazidime-avibactam against a challenge collection of Enterobacterales: Results from a multi-laboratory study. by Sader HS, Rhomberg PR, Chandrasekaran S, Trejo M, Fedler KA, Boyken LD and Diekema DJ published in J. Clin. Microbiol., 2020; 58 (4): e01757

Antimicrobial activity of telavancin tested in vitro against a global collection of gram-positive pathogens, including multidrug-resistant isolates (2015-2017). by Duncan LR, Sader HS, Huband MD, Flamm RK and Mendes RE published in Microb. Drug Resist.: in press, 2020.

Antimicrobial activity of cefoperazone-sulbactam tested against gram-negative organisms from Europe, Asia-Pacific, and Latin America. by Sader HS, Carvalhaes CG, Streit JM, Castanheira M and Flamm RK published in Int. J. Infect. Dis. 2020; 91: 32-37

Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. hospitals during 2014 to 2018. by Carvalhaes CG, Shortridge D, Sader HS and Castanheira M. published in Antimicrob. Agents Chemother. 2020; 64 (3):e02177

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY Program 2016-2018. by Pfaller MA, Carvalhaes C, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob Agents Chemother.: in press 2020.

Evaluation of antimicrobial effects of a new polymyxin molecule (SPR741) when tested in combination with a series of beta-Lactam agents against a challenge set of Gram-negative pathogens. by Mendes RE, Rhomberg PR, Lister T, Cotroneo N, Rubio A and Flamm RK published in Microb. Drug Resist.: in press, 2020

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2019; 96: 114833

Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination. by Castanheira M, Deshpande LM, Messer SA, Rhomberg PR and Pfaller MA published in Int. J. Antimicrob. Agents., 2020: 55 (1); 105799

In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. by Flamm RK, Shortridge D, Castanheira M, Sader HS and Pfaller MA. published in Antimicrob. Agents. Chemother. 63 (11): e01154, 2019.

The Infectious Diseases Society of America’s 10 x ’20 Initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): Is 20 x ’20 a possibility? by Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, Rodvold KA, Newland JG, Boucher HW and Infectious Diseases Society of A. published in Clin. Infect. Dis. 2019; 69 (1): 1-11

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. by Sader HS, Mendes RE, Pfaller MA and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (5): 1306-1310

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program. by Shortridge D, Pfaller MA, Streit JM and Flamm RK published in J. Glob. Antimicrob. Resist.: in press, 2019.

Resistance to Oral Antibiotics among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017. Lead author: IA Critchley, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1465